In a whirlwind of market reactions, biotech stocks Argenx ( NASDAQ:ARGX ) and Immunovant ( NASDAQ:IMVT ) emerged as frontrunners on Thursday, propelled by disappointing results from Japanese rival Chugai Pharmaceutical. The contrast in fortunes underscores the high stakes and volatile nature of the biotech industry, where a single clinical trial outcome can send...
After forming the gap at the market open , NASDAQ:ARGX has succeeded to close above the Red Line around the 206.5 .
IF it succeeds today or in an upcoming day to close with bullish strength considerably above the green line at around the 217 mark ,I think It is likely to continue up to around the 270-272 area even though price is now at an all time high...
